Global Cord Blood (CORBF) Competitors $1.75 0.00 (0.00%) (As of 10/10/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends CORBF vs. CSTL, INNV, FLGT, AUNA, CELC, SHCR, GRAL, EHAB, DCGO, and VMDShould you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Castle Biosciences (CSTL), InnovAge (INNV), Fulgent Genetics (FLGT), Auna (AUNA), Celcuity (CELC), Sharecare (SHCR), Grail (GRAL), Enhabit (EHAB), DocGo (DCGO), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry. Global Cord Blood vs. Castle Biosciences InnovAge Fulgent Genetics Auna Celcuity Sharecare Grail Enhabit DocGo Viemed Healthcare Global Cord Blood (NYSE:CORBF) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Do analysts rate CORBF or CSTL? Castle Biosciences has a consensus target price of $32.80, suggesting a potential upside of 15.90%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Global Cord Blood.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACastle Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in CORBF or CSTL? 92.6% of Castle Biosciences shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by insiders. Comparatively, 7.2% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor CORBF or CSTL? Castle Biosciences received 84 more outperform votes than Global Cord Blood when rated by MarketBeat users. CompanyUnderperformOutperformGlobal Cord BloodN/AN/ACastle BiosciencesOutperform Votes8463.16% Underperform Votes4936.84% Does the media prefer CORBF or CSTL? In the previous week, Castle Biosciences had 18 more articles in the media than Global Cord Blood. MarketBeat recorded 18 mentions for Castle Biosciences and 0 mentions for Global Cord Blood. Castle Biosciences' average media sentiment score of 0.87 beat Global Cord Blood's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Global Cord Blood Neutral Castle Biosciences Positive Is CORBF or CSTL more profitable? Global Cord Blood has a net margin of 0.00% compared to Castle Biosciences' net margin of -1.08%. Global Cord Blood's return on equity of 0.00% beat Castle Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Global Cord BloodN/A N/A N/A Castle Biosciences -1.08%-0.77%-0.68% Which has preferable valuation and earnings, CORBF or CSTL? Global Cord Blood has higher earnings, but lower revenue than Castle Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Cord Blood$196.12M1.08$79.04MN/AN/ACastle Biosciences$287.59M2.72-$57.47M-$1.15-24.61 Which has more volatility and risk, CORBF or CSTL? Global Cord Blood has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. SummaryCastle Biosciences beats Global Cord Blood on 10 of the 14 factors compared between the two stocks. Ad Angel PublishingWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. Get Global Cord Blood News Delivered to You Automatically Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORBF vs. The Competition Export to ExcelMetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE ExchangeMarket Cap$212.71M$2.00B$5.43B$19.35BDividend YieldN/A2.14%4.68%3.47%P/E RatioN/A16.43119.1527.07Price / Sales1.085.911,212.7217.92Price / Cash2.1110.5239.0120.74Price / BookN/A3.594.795.19Net Income$79.04M$69.56M$115.81M$980.15M7 Day PerformanceN/A1.52%-0.91%-0.74%1 Month Performance16.67%71.59%14.24%6.16%1 Year Performance40.00%19.66%24.07%22.68% Global Cord Blood Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORBFGlobal Cord BloodN/A$1.75flatN/A+41.1%$212.71M$196.12M0.001,200CSTLCastle Biosciences2.1377 of 5 stars$29.35+3.3%$32.80+11.8%+92.8%$810.27M$287.59M-25.52540Insider SellingShort Interest ↓News CoverageINNVInnovAge1.2461 of 5 stars$5.50+3.0%$6.50+18.2%-1.9%$747.93M$763.86M-22.922,350FLGTFulgent Genetics4.6586 of 5 stars$20.89+1.7%$30.00+43.6%-24.3%$625.11M$290.71M-3.751,184Short Interest ↓Positive NewsAUNAAuna3.9195 of 5 stars$7.15+1.4%$13.40+87.4%N/A$528.51M$4.23B0.0014,958News CoverageCELCCelcuity3.049 of 5 stars$15.04+1.5%$28.67+90.6%+54.7%$527.92MN/A-5.4140Analyst ForecastShort Interest ↑News CoveragePositive NewsSHCRSharecare1.458 of 5 stars$1.42flat$1.43+0.7%+52.9%$514.62M$403.73M-3.843,352GRALGrailN/A$13.03+3.7%N/AN/A$404.62M$109.74M0.001,360Insider BuyingEHABEnhabit3.5531 of 5 stars$7.48-1.2%$9.35+25.0%-17.2%$375.17M$1.04B-4.5110,800Short Interest ↓DCGODocGo2.5115 of 5 stars$3.35+6.3%$6.10+82.1%-45.2%$340.25M$742.84M16.754,164Gap DownVMDViemed Healthcare3.0365 of 5 stars$8.35+2.3%N/A+26.3%$324.23M$183.01M32.12630Short Interest ↓Positive News Related Companies and Tools Related Companies: CSTL Competitors INNV Competitors FLGT Competitors AUNA Competitors CELC Competitors SHCR Competitors GRAL Competitors EHAB Competitors DCGO Competitors VMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CORBF) was last updated on 10/11/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the n...InvestorPlace | SponsoredAI Expert Reveals New PickWhy You Shouldn't Pour All Your Money Into Nvidia Jeff Brown, who predicted Nvidia's rise, warns against pu...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
